Skip to Content

Sensipar Approval History

FDA Approved: Yes (First approved March 8, 2004)
Brand name: Sensipar
Generic name: cinacalcet
Dosage form: Tablets
Company: Amgen Inc.
Treatment for: Secondary Hyperparathyroidism, Hypercalcemia of Malignancy

Sensipar (cinacalcet) is a calcimimetic agent indicated for the treatment of secondary hyperparathyroidism in dialysis patients and for the treatment of hypercalcemia in patients with parathyroid carcinoma.

Development History and FDA Approval Process for Sensipar

Mar  8, 2004Approval Sensipar Amgen Inc. - Treatment for Secondary Hyperparathyroidism in dialysis patients

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.